Related Experiment Video

Updated: May 22, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Oncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm?

Keith A Lawson1, Don G Morris

  • 1Translational Research Laboratory, Department of Oncology, University of Calgary, Calgary, Alberta, Canada.

Expert Opinion on Biological Therapy
|May 9, 2012
PubMed
Abstract

Insights

Oncolytic viruses (OVs) show promise for treating metastatic renal cell carcinoma (mRCC) by leveraging its immune responsiveness. Further research in preclinical models and combination therapies is crucial for clinical translation.

Area of Science:

  • Oncolytic virotherapy
  • Renal cell carcinoma research
  • Immunotherapy

Background:

  • Metastatic renal cell carcinoma (mRCC) remains incurable despite targeted therapies.
  • mRCC's responsiveness to immunotherapy and molecular characteristics make it a candidate for oncolytic virus (OV) treatment.
  • OVs can exploit oncogenic pathways and stimulate anti-tumor immune responses.

Purpose of the Study:

  • To review evidence supporting oncolytic virotherapy for mRCC.
  • To highlight molecular and immunological features of mRCC exploitable by OVs.
  • To detail the mRCC tumor microenvironment and OV-restrictive factors.

Main Methods:

  • Discussion of current evidence for oncolytic virotherapy in mRCC.
  • Analysis of mRCC's molecular and immunological landscape.
  • Examination of the mRCC tumor microenvironment and its impact on OV efficacy.

Main Results:

  • OVs offer a potential therapeutic strategy for mRCC by engaging anti-tumor immunity.
  • Understanding the tumor microenvironment is key to overcoming OV resistance.
  • Preclinical models are essential for evaluating OV efficacy and immune response.

Conclusions:

  • Preclinical development should use immunocompetent models to assess anti-viral and anti-tumor immunity.
  • Combination therapies with existing mRCC treatments should be explored.
  • These strategies are vital for translating OVs into clinical applications for mRCC.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...